Cardiac Markers in Depressed Patients With Coronary Heart Disease - R01HL147862 (TREND-3)

Fatigue, Anhedonia and Cardiac Prognostic Markers in Depressed Patients With Coronary Heart Disease

Depression doubles the risk of death in patients with coronary heart disease (CHD), but so far, there is insufficient evidence that we can reduce the risk of death by treating depression. This study will investigate the cardiac risk markers that are associated with depression symptoms that remain despite treatment, and identify potential targets for their treatment. The results of the study will inform the development of more effective interventions to improve both depression and survival in patients with CHD.

Study Overview

• Status: Recruiting
• Conditions: Depression; Coronary Heart Disease
• Intervention / Treatment: Other: Other

Detailed Description

Depression is associated with an increased risk of cardiac morbidity and mortality in coronary heart disease (CHD). Although safe and modestly effective treatments for major depression exist, only about 30% of patients ever achieve full remission. CHD patients with depression symptoms that do not respond to treatment are at high risk for cardiac morbidity and mortality compared to those whose depression symptoms respond to treatment. Anhedonia and fatigue are among the most common symptoms to remain following treatment in both depressed CHD patients and in medically well psychiatric patients. In a recent study, the investigators found that several risk markers of cardiovascular morbidity and mortality including a high normal level of the thyroid hormone free thyroxine (FT4), low nocturnal heart rate variability, blunted circadian heart rate, and poor sleep quality predict depression treatment response and post-treatment symptoms of fatigue and anhedonia. It is unclear why these risk markers are associated with residual anhedonia and fatigue. Elevated cortisol levels, chronic sympathetic nervous system activation, reduced vagal modulation of HR, high levels of perceived stress, low level of physical activity, disordered sleep, and occult subclinical thyroid diseases are among the most plausible explanations. Any or all of these factors may explain the relationship between the risk markers and residual fatigue and anhedonia, and all are potentially modifiable and thus possible targets for future clinical trials. The purpose of the proposed research is to identify modifiable correlates of these risk markers and of fatigue and anhedonia in depressed patients with CHD. Study participants will be recruited from cardiology practices at Washington University School of Medicine. Potentially eligible patients will be scheduled for a structured clinical interview. Those who score ≥ 14 on the BDI-II and meet the DSM-5 criteria for major depression and no exclusion criteria will be enrolled. Participants will be evaluated by phone, or in person at the Behavioral Medicine Center at Washington University School of Medicine. The evaluation will be performed in the morning. An appointment will be made for a blood draw on a morning after a 12-hour fast to obtain a thyroid panel, lipid profile, plasma cortisol, C-reactive protein, and other biomarkers. Participants will be fitted with an ambulatory ECG monitor and a wrist actigraph that will be sent to them, and they will complete a battery of self-report inventories. The ECG monitor and actigraph will be worn for 48 hours on two consecutive weekdays to measure the ECG markers, activity levels, and sleep parameters. Participants will be compensated for their time upon return of the samples and equipment. This study will identify potential targets for adjunctive interventions to augment traditional depression treatments and thereby help to lay the groundwork for a randomized clinical trial to determine whether treating depression in patients with CHD can improve both depression and event-free survival.

• Study Type: Observational
• Enrollment (Estimated): 175

Contacts and Locations

• Study Contact: Name: Patricia A Herzing, RN; Phone Number: 314-286-1360; Email: herzingp@wustl.edu
• Study Contact Backup: Name: Jessica L Winker, MPH; Phone Number: 314-286-1313; Email: jessica.winker@wustl.edu

Study Locations

• United States
  • Missouri
    • Saint Louis, Missouri, United States, 63108
      • Recruiting
      • Washington University
      • Contact: Patricia A. Herzing, RN; Phone Number: 314-286-1360; Email: herzingp@wustl.edu
      • Contact: Jessica L. Winker, MPH; Phone Number: 314-286-1313; Email: jessica.winker@wustl.edu
      • Principal Investigator: Kenneth E Freedland, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Participants with Coronary Disease and Depressive Disorder

Description

Inclusion Criteria:

• Patients seen at the Washington University Medical Center with coronary heart disease (CHD) documented by coronary angiography or history of acute coronary syndrome (ACS).
• On a stable medication regimen (only minor changes in drug or dosage in last 30 days) are eligible for recruitment.
• Meet the diagnostic criteria for a depressive disorder, score ≥ 14 on the Beck Depression Inventory (BDI-II), and not meet any exclusion criteria.

Exclusion Criteria:

• Thyroid disease or thyroid medications.
• Moderate to severe cognitive impairment.
• Major psychiatric comorbidities.
• Taking antidepressants other than a selective serotonin reuptake inhibitor (SSRI).
• Suicidal features.
• Current substance abuse.
• New York Heart Association (NYHA) class III or higher or a recent (<3 months) acute coronary syndrome (ACS), coronary artery bypass graft surgery, cardiac hospitalization, or cardiac-related emergency department visit.
• Advanced malignancy, a disability that would prevent compliance with the study protocol, or physician or patient refusal.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Patients with medically stable coronary heart disease and Depressive Disorder	Other: Other; Patients with Coronary Heart Disease and Depressive Disorder are receiving routine treatment by their physician.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
This is our primary measure of depression severity.	Beck Depression Inventory (BDI-II) scale 0-63; higher score indicates a more severe depression	baseline contact

Collaborators and Investigators

• Sponsor: Washington University School of Medicine
• Investigators: Principal Investigator: Kenneth E Freedland, PhD, Washington University School of Medicine

Study record dates

Study Major Dates

• Study Start (Actual): December 1, 2020
• Primary Completion (Estimated): May 31, 2025
• Study Completion (Estimated): May 31, 2025

Study Registration Dates

• First Submitted: December 10, 2020
• First Submitted That Met QC Criteria: December 18, 2020
• First Posted (Actual): December 24, 2020

Study Record Updates

• Last Update Posted (Actual): March 21, 2024
• Last Update Submitted That Met QC Criteria: March 20, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Heart Diseases; Coronary Artery Disease; Myocardial Ischemia; Coronary Disease
• Other Study ID Numbers: R01HL147862 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: De-identified study data will be shared on request after the closure of the study.
• IPD Sharing Time Frame: The dataset is expected to be finalized in mid- to late-2025.
• IPD Sharing Access Criteria: Affiliation with a recognized research institution
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; ANALYTIC_CODE

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No